Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival
Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival
复制标题
DOI：
10.1093/annonc/mdg300
复制
发表时间：
2003-07-01
影响因子：
50.5
通讯作者：
Sledge, GW
中科院分区：
文献类型：
--
作者：
Miller, KD;Weathers, T;Sledge, GW
背景资料：由于筛选中枢神经系统（CNS）成像不常规进行，发病率和临床意义的隐匿性中枢神经系统转移在晚期乳腺癌是未知的。患者和方法：所有患者筛选参与四个临床试验之一，包括每个试验排除已知的中枢神经系统参与和需要筛选中枢神经系统成像的患者。从IU癌症中心肿瘤登记处比较确定了一组有症状的中枢神经系统转移的乳腺癌患者。结果：从1998年11月至2001年8月，进行了155项筛查成像研究。23例患者（14.8%）有隐匿性CNS转移。多因素分析显示HER-2过表达（P=0.02）和转移部位数（P=0.03）是CNS受累的预测指标。从转移开始的中位生存期（1.78年对2.76年; P
Background: As screening central nervous system (CNS) imaging is not routinely performed, the incidence and clinical relevance of occult CNS metastases in advanced breast cancer is unknown.Patients and methods: All patients screened for participation in one of four clinical trials were included; each of the trials excluded patients with known CNS involvement and required screening CNS imaging. A cohort of breast cancer patients with symptomatic CNS metastases was identified from the IU Cancer Center Tumor Registry for comparison.Results: From November 1998 to August 2001, 155 screening imaging studies were performed. Twenty-three patients (14.8%) had occult CNS metastases. HER-2 overexpression (P=0.02) and number of metastatic sites (P=0.03) were predictive of CNS involvement by multivariate analysis. Median survival from time of metastasis (1.78 versus 2.76 years; P